Evidence map›Paper›PMID 33422353›Full record

SynthesisEuropean urology2021

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.

Irene Casanova-Salas, Alejandro Athie, Paul C Boutros, Marzia Del Re, David T Miyamoto, Kenneth J Pienta, Edwin M Posadas, Adam G Sowalsky, Arnulf Stenzl, Alexander W Wyatt and 1 more

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Observational
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Irene Casanova-SalasVall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
Alejandro AthieVall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
Paul C BoutrosDepartments of Human Genetics and Urology, Institute for Precision Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Marzia Del ReUnit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
David T MiyamotoDepartment of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Kenneth J PientaThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Edwin M PosadasTranslational Oncology Program & Urologic Oncology Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Adam G SowalskyLaboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Arnulf StenzlDepartment of Urology, University Hospital Tübingen, Tübingen, Germany.
Alexander W WyattVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Joaquin MateoVall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: jmateo@vhio.net.
Vall d'Hebron Hospital Universitari · ESAzienda Ospedaliera Universitaria Pisana · ITCedars-Sinai Medical Center · USHarvard University · USHebron University · PSJohns Hopkins University · USNational Cancer Institute · USUniversity Children's Hospital Tübingen · DEUniversity of British Columbia · CAUniversity of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Mechanisms of resistance to treatment in aggressive prostate cancersZIABC011838 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SOWALSKY, ADAM · 2018 to 2025
$5.7M
Early detection of prostate cancer using circulating tumor DNAZIABC011680 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SOWALSKY, ADAM · 2016 to 2025
$2.7M
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate CancerU01CA214194 · NCI · EASTERN VIRGINIA MEDICAL SCHOOL · PI BOUTROS, PAUL CHRISTOPHER, KISLINGER, THOMAS · 2016 to 2021
$2.5M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011680NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS U01 CA214194
6 · The paper itself

Abstract

contextGenomic stratification can impact prostate cancer (PC) care through diagnostic, prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and spatial genomic heterogeneity of PC together with the challenges of acquiring metastatic tissue biopsies hinder implementation of tissue-based molecular profiling in routine clinical practice. Blood-based liquid biopsies are an attractive, minimally invasive alternative.

objectiveTo review the clinical value of blood-based liquid biopsy assays in PC and identify potential applications to accelerate the development of precision medicine. EVIDENCE ACQUISITION: A systematic review of PubMed/MEDLINE was performed to identify relevant literature on blood-based circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) in PC. EVIDENCE SYNTHESIS: Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve (genome, epigenome, transcriptome, and proteome) with tumor progression. Liquid biopsy tests encompass analysis of DNA, RNA, and proteins that can be detected in CTCs, ctDNA, or EVs. Blood-based liquid biopsies have demonstrated promise in the context of localized tumors (diagnostic signatures, risk stratification, and disease monitoring) and advanced disease (response/resistance biomarkers and prognostic markers).

conclusionsLiquid biopsies have value as a source of prognostic, predictive, and response biomarkers in PC. Most clinical applications have been developed in the advanced metastatic setting, where CTC and ctDNA yields are significantly higher. However, standardization of assays and analytical/clinical validation is necessary prior to clinical implementation. PATIENT SUMMARY: Traces of tumors can be isolated from blood samples from patients with prostate cancer either as whole cells or as DNA fragments. These traces provide information on tumor features. These minimally invasive tests can guide diagnosis and treatment selection.

Indexed as

Circulating Tumor DNANeoplastic Cells, CirculatingProstatic NeoplasmsBiomarkers, TumorClinical Decision-MakingHumansLiquid BiopsyMaleBiomarkers, TumorCirculating Tumor DNACirculating tumor cellCirculating tumor DNAExtracellular vesiclesGenomicsLiquid biopsyPrecision medicineProstate cancer

Identifiers

PMID33422353
PMCPMC8941682
OpenAlexW3119166731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.